- Fellowship - Memorial Sloan Kettering Cancer Institute (2004-2006), Urologic Oncology
- Internship/Residency - Duke University Medical Center (1998-2004), Urology
- Medical School - Jefferson Medical School (1990-1997)
Ganesh Raj, M.D., Ph.D.
- The Dr. Paul Peters Chair in Urology in Memory of Rumsey and Louis Strickland
- Genitourinary Cancer
- Bladder Cancer
Ganesh Raj, M.D., Ph.D., is a Professor of Urology and Pharmacology at UT Southwestern Medical Center and the holder of the Paul C. Peters Chair in Urology. He is also the co-leader of the Experimental Therapeutics program at the Harold C. Simmons Cancer Center, which is the largest program within the Cancer Center. He leads the Prostate Cancer programmatic efforts at UT Southwestern Medical Center, with the goal of a National Institutes of Health (NIH) Specialized Programs of Research Excellence (SPORE).
Dr. Raj joined the UT Southwestern faculty in 2006 after completing his urology training at Duke University Medical Center and his urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York.
Dr. Raj specializes in urologic oncology, including the treatment of high-risk prostate, bladder, kidney, and testis cancers. He is one of the leading urologic cancer surgeons in the country, with superb outcomes using open, laparoscopic, and robotic techniques. He has particular expertise in nerve-sparing techniques and in complex salvage procedures.
His clinical interests include optimizing oncologic and surgical outcomes for patients with urologic cancers using minimally invasive and multimodality approaches.
Dr. Raj is a national research and thought leader in prostate cancer. His basic science research is focused on the identification and targeting of molecular drivers of therapy resistance in innovative clinical model systems. In prostate cancer, his research team has identified critical drivers of advanced prostate cancer and developed novel small molecule therapeutic agents – peptidomimetics – against these drivers. His cutting-edge research program has received funding from the Prostate Cancer Foundation, the Department of Defense, the National Cancer Institute, private foundations, and pharmaceutical companies.
Dr. Raj is a rare surgeon scientist who was recently inducted in the prestigious American Society of Clinical Investigation, as only the third urologist ever. He has authored more than 140 publications in high-impact, peer-reviewed journals such as Nature, Journal of Clinical Oncology, Lancet Oncology, eLife, Cancer Research, and Molecular and Cellular Biology. He has remained at the cutting edge of both basic science and the surgical art. His work has recently expanded into overcoming therapeutic resistance in breast and pancreatic cancers.
Dr. Raj has received numerous honors for his work throughout his career, including first prize from the American Urological Association for his laboratory research on prostate cancer. He serves as a peer reviewer for many significant peer-reviewed journals in basic science, urology, and oncology and is frequently invited to speak at universities and national conferences.
He has been recognized as one of “America’s Best Doctors” and has received both the Patient’s Choice Award as one of Texas’ top physicians and the Compassionate Doctor Recognition Award.
Meet Dr. Raj
Urologist Ganesh Raj, M.D., Ph.D., helps people put urologic cancers in their past.
Dr. Raj is one of the nation’s leading urologic cancer surgeons and specializes in high-risk procedures for prostate, bladder, kidney, testis, and penile cancers. He has particular expertise in nerve-sparing techniques and in complex salvage procedures – surgeries for cancers that persist despite radiation or previous surgery.
"We can put these cancers in the rearview mirror for our patients."
Instead of dwelling on the negative aspects of cancer, he wants patients with aggressive urologic cancers like prostate cancer and bladder cancer to think, “I had cancer, I treated it, and I moved on.”
He brings a compassionate approach to each patient he sees and tries to find the best treatment for every individual.
“I approach every patient from a simple standpoint of, if this patient were my father, what would I do for him?” Dr. Raj says.
He promotes a multimodality approach to urologic cancers, meaning a mix of surgery, radiation, and chemotherapy – whatever treatment option UT Southwestern Medical Center’s urologic cancer team believes will work best for each patient. When possible, he will recommend minimally invasive robotic surgery to help patients get back to living their lives as soon as possible.
“For me, it’s more about giving patients multiple choices and making sure they understand what they are going into – the pros and the cons of a treatment,” he says.
In his research lab, Dr. Raj and his team focus on developing new therapeutics for prostate and bladder cancer. Among other work, his team has created a drug that uniquely targets androgen receptors in prostate cancer. That drug is moving toward clinical trials to test its effectiveness for patients.
- American Urological Association (2004)
- American Association of Cancer Research (2006)
- American Society of Clinical Investigation (2017), National Honor society for Physician scientists
- Society of Urologic Oncology
- Society for Basic Urology research (2016), president of society
- American Society of Clinical Investigation 2017, Nation's oldest medical honor society
- Sigma Xi Research Award (1st Place) 1994, Most outstanding basic science research of the year, Philadelphia Chapter, Sigma Xi Research Society, Philadelphia, PA
- AUA Circon Basic Science Research Award (1st Place) 2001, Laboratory research/ AUA Annual Meeting, Anaheim, CA
- AUA/Praecis Gerald P. Murphy Scholar 2002, Distinction in the study of prostate cancer, AUA Annual Meeting, Orlando FL
- Society of Memorial Sloan Kettering Research Award 2005, Awarded for perineural therapeutics and cavernous nerve injury, Society of Memorial Sloan Kettering
- ASCO Foundation Merit Award 2006, Awarded to the top-rated abstracts in prostate cancer, Prostate Cancer Symposium, San Francisco, CA
- ASCO Foundation Merit Award 2008, Awarded to the top-rated abstract in genitourinary oncology
- FASEB Conference Merit Award 2010, Awarded to the top-rated abstract in steroid signaling
- Freemasons Foundation Centre for Men's Health 2014, Visiting Lectureship, Adelaide Australia
- ASCO FOUNDATION MERIT AWARD 2008, Awarded to the top-rated abstract in genitourinary oncology
- FASEB CONFERENCE MERIT AWARD 2010, Awarded to the top-rated abstract in steroid signaling
- FREEMASONS FOUNDATION CENTRE FOR MENS HEALTH 2014, Visiting Lectureship, Adelaide Australia
Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.
Zhou H, Hallac RR, Yuan Q, Ding Y, Zhang Z, Xie XJ, Francis F, Roehrborn CG, Sims RD, Costa DN, Raj GV, Mason RP Diagnostics (Basel, Switzerland) 2017 Aug 7 3
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.
Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM Oncotarget 2015 Jan
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM Nucleic acids research 2015 Apr
Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation.
Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, Raj GV, Rossi R, Hammes SR The Journal of clinical investigation 2012 Jul 122 7 2469-81
The social network of PELP1 and its implications in breast and prostate cancer.
Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj G Endocrine-related cancer 2014 May
Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques.
Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV The Journal of urology 2008 Jan 179 1 75-9; discussion 79-80
Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.
Marian CO, Yang L, Zou YS, Gore C, Pong RC, Shay JW, Kabbani W, Hsieh JT, Raj GV The Prostate 2011 May 71 6 626-36
Surgery: The surgeon-scientist - a dying breed?
Woldu SL, Raj GV Nature reviews. Urology 2016 Dec 13 12 698-699
Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB BJU international 2017 Jun
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Dec JCO2017741173
Breast Tumor Kinase (Brk/PTK6) is Induced by HIF, Glucocorticoid Receptor and PELP1 Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina R, Seagroves TN, Lange CA Cancer research 2016 Jan
Progesterone receptor modulates ERa action in breast cancer.
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS Nature 2015 Jul 523 7560 313-7
Lymphadenectomy in management of invasive bladder cancer.
Youssef RF, Raj GV International journal of surgical oncology 2011 2011 758189
Mouse Spermatogenesis Requires Classical and Nonclassical Testosterone Signaling.
Toocheck C, Clister T, Shupe J, Crum C, Ravindranathan P, Lee TK, Ahn JM, Raj GV, Sukhwani M, Orwig KE, Walker WH Biology of reproduction 2015 Nov
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA Molecular cancer research : MCR 2018 Jul
Invited Minireview: Deciphering the cellular functions of PELP1.
Ravindranathan P, Lange C, Raj GV Molecular endocrinology (Baltimore, Md.) 2015 Jul me20151049
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, Welti J, Rodrigues DN, Dolling D, Figueiredo I, Sumanasuriya S, Crespo M, Aslam A, Li R, Yin Y, Mukherjee B, Kanchwala M, Hughes AM, Halsey WS, Chiang CM, Xing C, Raj GV, Burma S, de Bono J, Mani RS Cell reports 2018 Jan 22 3 796-808
Electrical Impedance Measurements of Biological Cells in Response to External Stimuli.
Mansoorifar A, Koklu A, Ma S, Raj GV, Beskok A Analytical chemistry 2018 Feb
Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer.
Miao L, Yang L, Li R, Nava Rodrigues D, Crespo M, Hsieh JT, Tilley WD, de Bono JS, Selth LA, Raj GV Cancer research 2017 Mar
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL Science advances 2016 Jun 2 6 e1501924
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Duan L, Rai G, Roggero C, Zhang QJ, Wei Q, Ma SH, Zhou Y, Santoyo J, Martinez ED, Xiao G, Raj GV, Jadhav A, Simeonov A, Maloney DJ, Rizo J, Hsieh JT, Liu ZP Chemistry & biology 2015 Sep 22 9 1185-96
Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
Welti J, Sharp A, Yuan W, Dolling DI, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate S, Carreira S, Boysen G, Chinnaiyan AM, Swain A, de Bono JS Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar
Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV Cancer research 2017 Jul
Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.
Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK eLife 2017 Aug 6
Expression of androgen receptor splice variants in clinical breast cancers.
Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA Oncotarget 2015 Nov
Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y Human pathology 2015 Dec 46 12 1829-35
Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK Molecular cancer research : MCR 2012 Jan 10 1 25-33
Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
Sen A, O'Malley K, Wang Z, Raj GV, Defranco DB, Hammes SR The Journal of biological chemistry 2010 Sep 285 37 28787-95
Corrigendum: Progesterone receptor modulates ERa action in breast cancer.
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS Nature 2015 Aug
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV European urology 2017 Dec
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.
Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM Nature communications 2016 Nov 7 13668
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast cancer research and treatment 2015 Mar
Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.
Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV Translational andrology and urology 2013 Sep 2 3 187-96
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD, Butler LM Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jul 18 13 3562-70
Dual roles of PARP-1 promote cancer growth and progression.
Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE Cancer discovery 2012 Dec 2 12 1134-49
A New Class of Agents for Estrogen-Receptor-Positive Breast Cancer.
Ekoue DN, Unni N, Raj GV Expert review of clinical pharmacology 2018 Feb
Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.
Nassar ZD, Aref AT, Miladinovic D, Mah CY, Raj GV, Hoy AJ, Butler LM BJU international 2018 Feb
Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
Paltoglou S, Das R, Townley SL, Hickey T, Tarulli G, Coutinho I, Fernandes RC, Hanson A, Denis I, Carroll J, Dehm SM, Raj GV, Plymate S, Tilley WD, Selth LA Cancer research 2017 May
Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard.
Raj GV, Bochner BH Seminars in oncology 2007 Apr 34 2 110-21
Ex vivo culture of human prostate tissue and drug development.
Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM Nature reviews. Urology 2013 Jun
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R Proceedings of the National Academy of Sciences of the United States of America 2014 Mar 111 11 4251-6
Tailoring Peptidomimetics for Targeting Protein-protein Interactions.
Akram ON, Degraff DJ, Sheehan JH, Tilley WD, Matusik RJ, Ahn JM, Raj GV Molecular cancer research : MCR 2014 Mar
Utility of 111 In-Capromab pendetide immunoscintigraphy in the detection of early recurrent disease after radical prostatectomy
Raj GV, Partin AW, Polascik TJ Cancer 2002 94 987-96
Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-KB
Raj GV, Sekula J, Kim J, Madden JF, Daaka Y Prostate 2004 61 105-113
Incidence of benign lesions for clinically localized renal masses < 7 cm in radiologic diameter: Influence of sex
Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P J Urology 2006 176 2391-2396
Radical cystectomy and lymphadenectomy for invasive bladder cancer: Towards the evolution of an optimal surgical standard
Raj, GV, Bochner B Seminars in Oncology 2006 In press
The Effect of Nephrectomy on Renal Function in Patients with Renal Cortical Tumors
Huang WC, Raj GV, Serio A, Vickers A, Russo P Lancet Oncology 2006 7(9) 735-40
Formulas estimating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer
Raj GV, Iasonos A, Herr HW, Donat SM, Formulas estimating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer J Clinic Oncology 2006 24(19) 3095-100
Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV, Iasonos A, Herr H, Donat SM Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Jul 24 19 3095-100
Utility of Pre-Operative Color Doppler Ultrasonography in Predicting the Histology of Renal Lesions
Raj GV, Bach A, Iasonos A, Korets R, Blitstein J, Hann L, Russo P J Urology 2007 177 53-58
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G The Journal of urology 2007 Apr 177 4 1283-6; discussion 1286
Preoperative nomogram predicting 12-year probability of metastatic renal cancer.
Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW The Journal of urology 2008 Jun 179 6 2146-51; discussion 2151
How to build and interpret a nomogram for cancer prognosis.
Iasonos A, Schrag D, Raj GV, Panageas KS Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 8 1364-70
The screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses.
Lucas SM, Nuss G, Stern J, Lotan Y, Sagalowsky AI, Cadeddu JA, Raj GV Cancer 2008 Nov 113 10 2681-6
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E Cancer 2011 Jan 117 2 276-82
Management of biochemical recurrence after primary localized therapy for prostate cancer.
Darwish OM, Raj GV Frontiers in oncology 2012 2 48
Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.
Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV Molecular endocrinology (Baltimore, Md.) 2012 Apr 26 4 550-61
Emerging drugs for prostate cancer.
Chung PH, Gayed BA, Thoreson GR, Raj GV Expert opinion on emerging drugs 2013 Dec 18 4 533-50
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.
Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV Nature communications 2013 May 4 1923
Emerging therapies in castration resistant prostate cancer.
Thoreson GR, Gayed BA, Chung PH, Raj GV The Canadian journal of urology 2014 Apr 21 2 Supp 1 98-105
Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA Oncogene 2014 Jan
Assocation between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract
Raj GV, Bochner BH, Vickers A, Teper E, Lin O, Donat SM, Herr H, Dalbagni G J Urology June 2006 175(6) 2038-2041, discussion 2041
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer
Raj GV, Tal R, Vickers A, Bochner BH, Serio A, Donat SM, Herr H, Olgac S, Dalbagni G Cancer November 2006 107(9) 2167-72
Natural history of positive urinary cytology after radical cystectomy
Raj GV, Bochner BH, Serio AM, Vickers A, Donat SM, Herr H, Lin O, Dalbagni G J Urology November 2006 176(5) 2000-5
- Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.
- Urologic cancers
- Development of targeted therapeutics
- Development of primary models of prostate and bladder cancers
- Androgen receptor signaling
- Genitourinary Cancer
- Bladder Cancer
- Kidney Cancer
- Prostate Cancer
- Testicular Cancer
- Male Urology
- General Urology